Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.21.1
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended
Aug. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Jan. 31, 2018
Commitments and Contingencies (Details) [Line Items]        
Total expensed   $ 658,000 $ 28,000  
Total Payments   1,033,000 87,000  
Accrued and payable   240,000 23,000  
Prepaid expenses and other current assets   607,000 $ 58,000  
Upfront payments       $ 25,000
Research and development expense   $ 24,215    
Granted period   5 years    
Patents [Member]        
Commitments and Contingencies (Details) [Line Items]        
Net revenue, percentage   50.00%    
EU Grant [Member]        
Commitments and Contingencies (Details) [Line Items]        
Research and development expenses percentage   50.00%    
Operating Lease [Member]        
Commitments and Contingencies (Details) [Line Items]        
Lease term, description the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was approximately $2,000, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.      
BioNumerik Pharmaceutical [Member]        
Commitments and Contingencies (Details) [Line Items]        
Upfront payments   $ 25,000    
Commitments and contingencies, description   In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.